



NEWSLINE

A PUBLICATION OF THE COLLEGE ON PROBLEMS OF DRUG DEPENDENCE, INC.
Volume Nine, Number Two • January 2005

CPDD President's Column

The Agenda Continues

Warren K. Bickel, Ph.D.
President

Openness and inclusion are two key themes that I have set as the agenda for my presidency as I outlined in my first column. Here in the second newsletter of this year, the agenda continues. This newsletter is brief, but timely and contains important information for the College.

First, in this newsletter we start what I hope will be a new tradition of asking candidates for president to write a vision statement. Specifically, Drs. Iguchi and Kosten were asked to write a couple of paragraphs describing their vision of what they would strive to accomplish as president. By asking the candidates to provide these statements, I hope the membership will be able to vote with more information.

Second, in this newsletter for the first time we include a brief report of what transpired at the Interim Board Meeting in December so that the membership can be informed of the actions of the College. I would like to thank Dr. Cunningham, President-Elect of the College, for developing that report!

Finally, I invite you to email me (wbickel@uams.edu) with your suggestions and thoughts for other ways to provide greater openness and to facilitate inclusion in the activities of the College.

The previous issue of *Newsline* described a Minority Travel Award Program. The proper title is the *CPDD Primm-Singleton Minority Travel Award*. Drs. Beny Primm and Edward Singleton played integral roles in increasing the number of minority CPDD members and minority participation at the annual meeting. For information about the CPDD Primm-Singleton Minority Travel Award visit the CPDD website at www.cpdd.org.

Board of Directors Interim Meeting

President Warren Bickel called the interim meeting of the CPDD Board of Directors to order at 9:00 a.m., December 10, 2004. The daylong meeting covered many issues and initiatives relevant to the college membership and the most important are reported briefly here.

Survey of Membership & Meeting Participants

Under the leadership of BOD Member Margaret Ensminger, the CPDD undertook a survey of the membership concerning the June 2004 meeting; this survey was conducted using an online survey mechanism known as Survey Monkey. Of the 1255 individuals sur-

veyed, the response rate was 43%. Overall, the quality of the presentations (the plenary session, symposia, oral and poster session, workshops) as well as the quality of informal interactions rated very highly. Issues related to the meeting venue (e.g., sound audible from adjacent rooms) were discussed and will be addressed. A subcommittee of BOD members has volunteered to investigate the best means by which to continue to survey the membership and meeting participants, and also to distill the best information from the collected data. A more detailed description of the results of the survey can be found in the last *Newsline* published in November that can be

Continued on page 2

BOD Interim Meeting Report *continued from page 1*

found at

<http://www.cpdd.vcu.edu/NewslineNov04.pdf>.

2005 Scientific Program

The Chair of the Program Committee, Sharon Walsh, presented the list of the symposia chosen for the upcoming 2005 meeting. The committee accepted nine full symposia, nine mini-symposia and 10 workshops. Two Presidential lectures by Harel Weinstein and Trevor Robinson will be scheduled. BOD members will monitor the attendance and success of the session during the meeting.

Drug Evaluation Committee Liaison Committee

The role of this committee is to bridge the activities of the Drug Evaluation Committee (DEC) with the activities and goals of the CPDD. The Chair of the Liaison Committee, Steve Negus, has prepared a brief description of the DEC (chaired by Jim Woods) and how CPDD members can be involved in their activities [see *The Drug Evaluation Committee on page 4*]. In addition, the DEC Liaison Committee has been renamed the "Committee on Abuse Liability".

2006 Nominations Committee

The 2006 Nominations Committee was composed of elected members (K. Brady, S. Comer, L. Dykstra, S. Holtzman) and BOD members (N. Ator, N. Goeders, S. Izenwasser, H. Loh) and chaired by the President-elect, K. Cunningham. Neico Smith in the CPDD office provided support for the committee's activities. Committee deliberations resulted in the selection of a slate for President-elect and four BOD members. The nominees for President-elect are Martin Iguchi and Tom Kosten. [Vision statements for each of the candidates for President-Elect can be found beginning on [page 3](#)]. Ballots for President-elect and the slate of BOD members for Position 1 (Andrew Coop, Toby Eisenstein, Richard Weber), Position 2 (Leonard Howell, Michael Nader, Linda Porrino), Position 3 (Thomas Kelly, A. Thomas McLellan, Charles O'Keeffe) and Position 4 (James

Cornish, Carl Hart, Alison Oliveto) were mailed to all members before Christmas with ballots due in the CPDD office at the end of January.

Drug and Alcohol Dependence

The Editor-in-Chief of DAD, Bob Balster, announced the retirement of Co-Editor Ian Stolerman, a position he has held for 12 years. The CPDD BOD and membership are extremely grateful to Dr. Stolerman for his years of service to DAD and CPDD. In the wake of this change in editorial leadership and the great success of the journal, Dr. Balster presented the proposed editorial structure for DAD that will include recruitment of several associate editors to oversee journal submission and review. Although not yet finalized, this structure will include associate editors to oversee several content areas. As this new initiative at DAD evolves, more information will be provided to the membership.

Under the guidance of the chair of the Publications Committee, Nick Goeders, the CPDD has successfully negotiated a new and improved 5-year contract with the DAD publisher Elsevier.

Other Publications

President Bickel announced the reinvigoration of the CPDD newsletter *Newsline* which will be published 3 times per year; after the two Executive Board meetings (Fall and Spring) and the interim BOD meeting in December. Examples of material to be published include a brief overview of the BOD meetings as well as interviews of CPDD scientists, beginning with previous Eddy award winners. The *Newsline* will be published electronically by editor Dave Wessinger and distributed via the CPDD listserv and posted to the CPDD website. Bill Dewey reported that the CPDD would continue to publish selected parts of the Annual Scientific Meeting, such as the introductions to the Eddy and Fischman Awards, synopses of the symposia, and the DEC reports, in the *NIDA Research Monograph Series*.

CPDD membership includes a subscription to Drug and Alcohol Dependence, ranked among the most cited drug abuse research journals.

Continued on page 3

BOD Interim Meeting Report *continued from page 2*

Washington News

The CPDD Public Policy Officer, Bill Dewey, reported on the budget approved for NIH and NIDA for 2005. Overall, it appears that NIDA will receive an estimated 1.6% increase. Given inflation, this will be a decrease in the NIDA budget. We should engage in efforts to enhance the NIDA budget.

Friends of NIDA

Bill Dewey also discussed the Friends of NIDA (FON), which was initiated in January of 2004 with goals to improve the public impression of drug abuse research efforts and to encourage improvements in the NIDA budget. The FON Board of Advisors includes former NIDA directors, and two former congressional chairs. Financial resources are

being solicited. The FON is planning four meetings on Capitol Hill to pursue their goals.

On-line Public Advocacy

President-elect Kathryn Cunningham proposed that CPDD utilize an on-line public advocacy tool (Capwiz®; Capitol Advantage) to help bridge the activities of CPDD and its Washington representatives with the membership. A decision to explore this option was made and additional information concerning the use of Capwiz will be forthcoming.

Conflict of Interest Policy

A subcommittee of the BOD (Chair C.-E. Johanson, W. Bickel, H. Kleber, T. Crowley) has agreed to develop a conflict of interest policy for CPDD by the 2006 meeting.

– Contributed by Kathryn Cunningham,
CPDD President-Elect

CPDD has been in existence since 1929 and is the longest standing group in the United States concerned with research on problems of drug dependence

CPDD President-Elect Nominee's Vision Statements

Martin Y. Iguchi, Ph.D.

CPDD is widely recognized as the premier scientific membership organization focusing on the problems of drug dependence. This recognition is a result of our long history of bringing science to bear on the problems of drug dependence, dating back to the early work of the committee in 1929, as well as to the continuing scientific excellence demonstrated by our membership over the years. Stewardship of this organization brings great responsibility to respond to the challenges of the day, while looking ahead and planning for problems on the horizon. I recognize that increasingly, CPDD leadership must take an active role in monitoring and responding to the political environment, with a need for attention to issues such as funding for NIDA/NIH; defending the relevance of basic science research; and advocating for policies informed by science. That said, my priorities are basic:

- 1) Stay focused on science, scientific quality, and the defense of basic science;
- 2) Increase the diversity of scientific research presented in CPDD forums while promoting racial and cross-national diversity in our membership;
- 3) Improve communications and increase operational transparency between CPDD leadership, members, potential members, and constituents; and,
- 4) Advocate for informed decision-making as applied to the problems of drug dependence and promote a dialogue between researchers, decision-makers, and the public.

Martin Iguchi is a Professor in Public Health at the University of California-Los Angeles and Director of the Drug Policy Research Center at the RAND Corporation. He has been a member of the College since 1994 and is currently a Regular Member and on the Board of Directors.



Continued on page 4

President-Elect Vision Statements – Continued from page 3

Thomas R. Kosten, M.D.



As President of CPDD, I would be a strong leader who openly and inclusively listens to our member’s needs and develops CPDD’s vision by acting on those needs. To maintain CPDD as open and inclusive, I hope to use our Newsletter, annual meeting (with Margaret Ensminger’s meeting survey), and email for science and to encourage advocacy, such as Bill Dewey’s national foundation supporting addictions research.

A decade ago, I proudly and enthusiastically voted in the CPDD board to make us a membership College. I again consider myself a leader for transitions and difficult times like NIH’s funding plateau. As President, I would improve our members’ chances to obtain resources for advancing addiction science, through my long-term relationships with Nora Volkow and Westley Clark, Directors of NIDA and CSAT.

A few personal details include serving twice on the CPDD Board of Directors (1988-92 and 2004-present), service on many CPDD committees (Program Committee Chair) and 25 years of tireless, if tiresome, CPDD presentations. I have led the American Academy of Addiction Psychiatry (AAAP), as President. I was a Congressional Fellow overseeing NIH and FDA funding and am a fellow of CPDD, APA and ACNP and received CPDD’s Cochin and ACNP’s Elkes awards. Editorial boards include *Drug and Alcohol Dependence* and Deputy Editor of the *American Journal on Addictions* and *American Journal of Drug Alcohol Abuse*. I conduct clinical research as Psychiatry Professor and former VA Chief at Yale.

Thank you for the honor of this Presidential nomination, and I promise humility and good humor, which the Board of Directors will appreciate.

Tom Kosten is a Professor in Psychiatry at Yale University School of Medicine and former Chief of Psychiatry at the VA Connecticut Healthcare System. He has been a member of the College since its inception and is currently a Director and Fellow. He received a Travel Award in 1985 and also won the Joseph Cochin Young Investigator Award in 1990.

The Drug Evaluation Committee

At the CPDD 2004 Interim Board Meeting, the Committee on Abuse Liability Testing was charged with the task of clarifying how CPDD members could participate in the activities of the Drug Evaluation Committee. The following text addresses this charge.

What is the Drug Evaluation Committee?

The Drug Evaluation Committee (DEC) is an independent consortium of investigators, chaired by Jim Woods at the University of Michigan. The DEC conducts preclinical abuse liability testing for clients in academia, industry and government. This service is provided free-of-charge to the compound submitter. Funding is provided almost entirely by grants awarded to DEC Members. CPDD provides only nominal funding for administrative expenses, and CPDD provides no funding for research supplies, equipment or personnel. CPDD

does not control the DEC, but rather supports its mission as one expression of a more general interest in abuse liability testing. Further information can be found on the CPDD website at <http://www.cpdd.vcu.edu/images/dec.pdf>.

What does participation in the DEC involve? Participation in the DEC may involve

- (a) receipt, secure storage, and handling of coded compounds from the Biological Coordinator (Andy Coop),
- (b) testing of coded compounds in assays thought to be indicative of abuse liability,
- (c) preparation of reports to summarize results, and
- (d) attendance at an annual meeting of DEC members to compile an annual report.

Continued on last page

CPDD OFFICERS

WARREN K BICKEL, PHD,
PRESIDENT

KATHRYN A. CUNNINGHAM, PHD,
PRESIDENT-ELECT

CHRIS-ELLYN JOHANSON, PHD,
PAST-PRESIDENT

DOROTHY K. HATSUKAMI, PHD,
TREASURER

MARTIN W. ADLER, PHD,
EXECUTIVE OFFICER

BOARD OF DIRECTORS

LESLIE AMASS, PHD

JAMES C. ANTHONY, PHD

NANCY A. ATOR, PHD

ANNA ROSE CHILDRESS, PHD

THOMAS J. CROWLEY, MD

SAMUEL A. DEADWYLER, PHD

WILLIAM L. DEWEY, PHD

NICHOLAS E. GOEDERS, PHD

MARTIN Y. IGUCHI, PHD

SARI IZENWASSER, PHD

HERBERT D. KLEBER, MD

THOMAS R. KOSTEN, MD

HORACE H. LOH, PHD

S. STEVENS NEGUS, PHD

SHARON L. WALSH, PHD

WILLIAM D. WESSINGER, EDITOR M.W. ADLER, EXECUTIVE OFFICER CPDD PUBLICATIONS COMMITTEE

Nicholas E. Goeders, Chair
Warren K. Bickel
Rebecca M. Craft
Richard De La Garza
Kenzie L. Preston
Beatriz A. Rocha
Stacey C. Sigmon
Sandra P. Welch

Send materials for **NEWSLINE** to:

William D. Wessinger
Univ. of Arkansas for Medical Sciences
Dept. of Pharmacology & Toxicology
4301 W. Markham Street, Box 611
Little Rock, AR 72205

Phone (501) 686-5514

Fax (501) 686-5521

Email: wdwessinger@life.uams.edu

Drug Evaluation Committee – Continued from page 4

How does one become a participant in the DEC? New participants are recruited to the DEC as needed, and participation is voluntary. In 2004, research under the auspices of the DEC was performed at six different laboratories run by six different CPDD members, and two of these sites participated for the first time in 2004. Thus, participation in the DEC is intended to be flexible to permit rapid adaptation to the evolving needs for abuse liability testing. New participants are recruited to the DEC according to the following guidelines.

- (a) The investigator must have the technical expertise and resources to implement procedures deemed necessary by the DEC.
- (b) The investigator must have independent financial resources to support DEC-related activities. The DEC does not provide financial support for its members. CPDD

provides nominal funding for administrative costs, but CPDD does not provide funding for research supplies, equipment or personnel.

- (c) The investigator must be willing and able to cooperate with the administrators and other members of the DEC and to be responsive to the mission of the DEC as articulated by the DEC leadership. Optimal abuse liability testing requires a coordinated response between many laboratories, and the success of the DEC in achieving its mission depends on efficient and cooperative interactions.

Investigators interested in participating in the DEC can contact the DEC Chairman, Jim Woods, to explore the need for new participants. Future areas of focus are likely to include abuse liability testing of cannabinoid and nicotinic drugs.

– Contributed by Steve Negus,
Chair, Committee on Abuse Liability

Benefits of Membership to CPDD

- A subscription to *Drug and Alcohol Dependence*, which has the highest impact factor among substance abuse journals (not included in student membership).
 - Reduced registration fees to attend the Annual Scientific Meeting.
 - Eligibility to sponsor abstract submissions for presentations at the Annual Meeting (not for Student Members)
 - Eligibility to submit abstract for Late-breaking News session.
 - Impact on public policy, including educating our representatives and other governmental officials on the need to support addiction research, ensuring the science base for new policies as well as programs dealing with human and animal research issues.
 - Mentorship activities for trainees and early-career scientists.
 - Opportunities to serve on CPDD committees.
 - Access to Members Only section of CPDD website, containing directory information, easy email to other members and committee reports.
 - Membership Listserv, for rapid communication of items of interest to the entire membership and posting of job opportunities.
- Membership categories include Student or In-Training, Associate and Full Member categories. The cost of annual membership is \$95 (\$35 for Student and In-Training Members). Additional information about the College, membership criteria and student benefits can be obtained at the CPDD website
- <http://www.cpdd.org>.